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Myeloperoxidase in kidney disease.
In glomerular and tubulointerstitial disease,
polymorphonuclear- and monocyte-derived reactive oxygen
species may contribute to oxidative modification of proteins,
lipids, and nucleic acids. In part, the processes instigated
by reactive oxygen species parallel events that lead to the
development of atherosclerosis. Myeloperoxidase (MPO),
a heme protein and catalyst for (lipo)protein oxidation is
present in these mononuclear cells. The ability of MPO to
generate hypochlorous acid/hypochlorite (HOCl/OCl−) from
hydrogen peroxide in the presence of chloride ions is a unique
and defining activity for this enzyme. The MPO-hydrogen
peroxide-chloride system leads to a variety of chlorinated
protein and lipid adducts that in turn may cause dysfunction
of cells in different compartments of the kidney. The aim of
this article is to cover and interpret some experimental and
clinical aspects in glomerular and tubulointerstitial diseases
in which the MPO-hydrogen peroxide-chloride system has
been considered an important pathophysiologic factor in the
progression but also the attenuation of experimental renal
disease. The colocalization of MPO and HOCl-modified
proteins in glomerular peripheral basement membranes
and podocytes in human membranous glomerulonephritis,
the presence of HOCl-modified proteins in mononuclear
cells of the interstitium and in damaged human tubular
epithelia, the inflammation induced and exacerbated by MPO
antibody complexes in necrotizing glomerulonephritis, and
the presence of HOCl-modified epitopes in urine following
hyperlipidemia-induced renal damage in rodents suggest
that MPO is an important pathogenic factor in glomerular
and tubulointerstitial diseases. Specifically, the interaction of
MPO with nitric oxide metabolism adds to the complexity of
actions of oxidants and may help to explain bimodal partly
detrimental partly beneficial effects of the MPO-hydrogen
peroxide-chloride system in redox-modulated renal diseases.
Neutrophilic granulocytes are one of the most pro-
fessional phagocytes that represent the first line of
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defense against invading bacteria, viruses, and fungi. Neu-
trophils ingest microorganisms into intracellular com-
partments called phagosomes, to which they direct an
arsenal of cytotoxic agents. Phagocytosing neutrophils
undergo a burst of oxygen consumption via the nicoti-
namide adenine dinucleotide phosphate (NADPH) oxi-
dase complex leading to generation of superoxide anions
plus a range of other reactive oxygen (hydroxyl radicals,
hydrogen peroxide, hypochlorous acid) and reactive ni-
trogen species (nitric oxide radicals, peroxynitrite) (for
review see [1]). Observations in humans and animals in-
dicated that myeloperoxidase (MPO) holds a central role
in microbial killing. Up-regulation of MPO gene expres-
sion in activated phagocytes would seem consistent with
the presumed antimicrobial function of the enzyme in
these cells. Recent investigations revealed a crucial role
of MPO in chronic, nonmicrobial inflammatory processes
such as neurodegenerative disease and atherosclerosis
(for review see [2]). In addition, epidemiologic data sup-
ported a relationship between MPO polymorphism in
humans and the risk for lung, larynx, and esophageal can-
cer and cardiovascular disease in end-stage renal disease
(ESRD) patients. Since phagocytes (neutrophils, mono-
cytes, and macrophages, respectively) are considered
essential effector cells in (auto)-immunologic and de-
generative kidney diseases, it is reasonable to assume
a contribution of MPO during these processes. This re-
view summarizes the biochemical features of MPO and
presents recent evidence for MPO as a catalyst for ox-
idation in the pathophysiology of kidney diseases; fur-
thermore, reactions that connect the MPO-hydrogen
peroxide-chloride system with pathways of other reac-
tive oxygen and nitrogen species will be described in the
context of renal diseases.
MYELOPEROXIDASE
The glycosylated arginine-rich, extremly basic MPO
protein [isoelectric point (IP) > 10] [1, 3] is comprised
of two subunits, encoded within a single mRNA. The ap-
proximately 83 kD precursor polypeptide is posttransla-
tionally processed to produce a 59 to 64 kD heavy subunit
and a 14 kD light subunit. Two of each subunits are
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Fig. 1. Three major pathways leading to formation of reactive oxidants via the myeloperoxidase (MPO)-hydrogen peroxide-system. Adapted and
modified from references [2, 10]. Abbreviations are: Tyr, tyrosine; Tyr◦, tyrosyl radical; NO2◦, nitrogen dioxide radical; NO2−, nitrite.
assembled with heme molecules to produce the func-
tional enzyme (donor:hydrogen peroxide, oxidoreduc-
tase, EC 1.11.1.7). MPO is stored in primary azurophilic
granules of leukocytes and the enzyme accounts for
up to 5% and 1% of total cell protein content,
in neutrophilic polymorphonuclear leukocytes (neu-
trophils) and monocytes, respectively. Although earlier
reports suggested that neither MPO mRNA nor pro-
tein is present in mature macrophages, MPO is present
in various macrophage subpopulations (e.g., Kupffer
cells [4], alveolar macrophages and microglia [5]), and
macrophages present in advanced atherosclerotic lesions
[6–8] hinting at a specific function of MPO during host
defense, tumor surveillance, and inflammation. Alterna-
tively, macrophages can ingest (senescent) neutrophils
or neutrophil granules that provide the macrophages
with this neutrophil peroxidase. Macrophages exposed
to enzymatically active MPO exhibited enhanced se-
cretion of cytokines including tumor necrosis fac-
tor a(TNF-a), interleukin-1 (IL-1), and interferons,
and increased capacity to phagocytose and to kill
microorganisms.
Following phagocyte activation by a variety of stimuli,
leading to generation of oxygen, superoxide anion radi-
cal and its dismutation product, hydrogen peroxide, MPO
is secreted into both the phagolysosomal compartment
and the extracellular milieu. A kinetic model for MPO
suggested that at ground state, MPO exists in the fer-
ric [Fe(III)] form; however, different stages of activation
depending on the respective ligand have been proposed
[2, 3]. At physiologic plasma concentrations (approx-
imately 100 mmol/L), chloride is a preferred sub-
strate for MPO and hypochlorous acid/hypochlorite
(HOCl/OCl−), a potent chlorinating oxidant, is formed.
Both, MPO and HOCl appear critical for oxidative
killing. Neutrophils isolated from the blood of MPO-
deficient individuals kill poorly a variety of microorgan-
isms and inhibitors of MPO impair killing by normal
cells. Excessive production of HOCl causes tissue damage
and scavenging of HOCl by taurine significantly inhibits
or reverses the deleterious effect of this highly reactive
oxidant. Indeed, under in vivo and in vitro conditions,
HOCl reacts with a wide range of oxidizable biomolecules
containing thiols, nitrogen compounds, or unsaturated
double carbon bonds. The main biologic chlorination re-
actions are with pyridine nucleotides, cholesterol, and
unsaturated lipids to give chlorohydrins and with amine
groups to give chloramines, which are in turn powerful
oxidants (Fig. 1). However, under acidic conditions and
in the presence of chloride ions the formation of chlo-
rine gas is favoured. Hazen et al [9] could show that hu-
man neutrophils employ chlorine gas as an oxidant during
phagocytosis and that chlorine gas derived from HOCl is
the chlorinating intermediate in the oxidation of choles-
terol and cholesterol-enriched low density lipoprotein,
respectively.
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Human phagocytes use the MPO-hydrogen peroxide-
chloride system to generate a family of tyrosyl radical
addition products [10] (Fig. 1). Both chlorinated ty-
rosines (e.g., 3-chlorotyrosine and 3,5-dichlorotyrosine)
and chlorohydrins may be used as biomarkers for the
estimation of chlorinated molecules [11]. Independent
immunohistologic confirmation of a role for chlorinat-
ing oxidants, primarily chloramines, may be achieved
with specific monoclonal antibodies [7, 12] in those tis-
sues susceptible to MPO-mediated chloramine formation
[7, 13–15]. In addition to generation of reactive oxygen
species, MPO-generated nitrogen species may be consid-
ered to represent alternative biomarkers for the effect of
MPO [16] (Fig. 1). MPO may use nitrite, the major end
product of nitric oxide radical metabolism, as a substrate
to nitrate protein tyrosine residues and to initiate lipid
peroxidation; nitrogen dioxide radical, the one electron
oxidation product of nitrite, has been implicated in this
process [17]. MPO may also generate a nitrating inter-
mediate through secondary reaction of HOCl with nitrite,
presumably forming nitryl chloride as reactive intermedi-
ate. Thus, MPO-dependent direct and indirect generation
of reactive nitrogen species could provide an alternative
route leading to formation of proatherogenic and proin-
flammatory (lipo)protein nitration adducts commonly ac-
complished by peroxynitrite. Peroxynitrite, formed from
nitric oxide and superoxide anion radical, may lead to
(lipo)protein nitration and peroxidation in the pres-
ence of carbon dioxide, presumably via intermediate
formation of nitrosoperoxocarbonate and subsequent
formation of nitrogen dioxide radical [16, 17]. From these
observations, it is intriguing to speculate that the MPO
pathway is coupled to the peroxynitrite pathway and
that compensatory mechanisms between both pathways
may be functional in the kidney probably under diabetic
conditions. Reports on peroxynitrite-induced injury in
diabetic nephropathy have been published [18] and treat-
ment of nonobese diabetic mice with peroxynitrite scav-
engers prevented the development of diabetes mellitus in
these animals [19]. A recent in vitro study performed in
proximal tubular epithelial cells revealed that high levels
of glucose cause generation of peroxynitrite leading to
caspase-mediated apoptosis in these cells [20].
Indeed, the role of glucose in oxidative stress-induced
kidney injury has been extensively documented. Chronic
hyperglycemia contributes to diabetic complications
through the formation of advanced glycation end prod-
ucts (AGEs), which are irreversibly formed biochem-
ical end products of nonenzymatic glycation. In vitro
experiments have shown that synthesis of acrolein,
2-hydroxypropanal, and glycoaldehyde required chlo-
ride, hydrogen peroxide, and MPO, respectively. Also
activated neutrophils employ MPO to generate these
aldehydes. In particular, a-hydroxyaldehyde, formed
from L-serine, mediates protein cross-linking and forma-
tion of Ne-(carboxymethyl)lysine, a characteristic AGE
[21]. These observations were the first to indicate that
the MPO-hydrogen peroxide-chloride system of human
phagocytes contributes to formation of AGEs which
could act as mediators of inflammation and monocyte ac-
tivation in chronic renal failure. The candidate receptor
for AGEs (RAGE) is expressed in rat, mouse, and hu-
man mesangial cells. The functional in vivo importance of
the AGE-RAGE system in the development of diabetic
nephropathy is underlined in a transgenic mouse model
overexpressing RAGE. When these mice were made di-
abetic by crossbreeding with another transgenic mouse
model deficient in the islet production of insulin, the
resultant double transgenic animals developed renal in-
sufficiency and advanced glomerulosclerosis having some
resemblence to human diabetic nephropathy [22].
EXPRESSION OF MPO IN KIDNEY DISEASE
Many authors demonstrated the presence of MPO-
containing cells as well as MPO protein and activity
in many renal diseases [14, 23–25]. The adherence of
neutrophils to the glomerular basement membrane and
the degradation of the basement membrane by oxidants
at sites of attachment [26] pointed toward a direct in-
volvement of MPO. In vivo experiments (i.e., perfusion
with MPO followed by nontoxic concentrations of hydro-
gen peroxide and chloride ions) revealed MPO-mediated
glomerular disease resulting in glomerular morphologic
changes, endothelial and mesangial cell injury, activation
of platelets, and subsequent proliferative responses mim-
icking inflammatory and proliferative glomerulonephritis
in humans [27].
Originally, MPO activity from inflamed kidneys could
not be demonstrated in a model of pyelonephritis even
though the presence of large numbers of neutrophils was
confirmed histologically [28]. However, the use of spe-
cific techniques allowed the assessment of MPO activity
in whole kidney tissues by measuring hydrogen peroxide–
dependent oxidation of 3,3′,5,5′-tetramethylbenzidine
[29] or o-dianisidine [23]. Hillegass et al [23] finally
demonstrated that MPO activity from inflamed kidney
was significantly greater than that from control tis-
sue. Western blotting experiments revealed immunore-
active MPO heavy subunit in nephrectomy specimens
from controls and patients with nephrosclerosis but to
a higher extent in nephrectomies from patients with
interstitial nephritis, pyelonephritis, and reflux nephropa-
thy [14]. Immunohistochemistry confirmed the presence
of MPO in interstitial cells and atrophic epithe-
lial cells. Colocalization of MPO and HOCl-modified
epitopes at the glomerular basement membrane in
membranous glomerulonephritis [14, 15] supported the
participation of the MPO-hydrogen peroxide-chloride
system in glomerular dysfunction [27, 30]. Measurement
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of urinary MPO was discussed as a possible noninva-
sive diagnostic marker for renal graft monitoring [31],
although the specificity of this test vis a vis bacte-
rial infection can be doubted. Nevertheless, the pres-
ence of HOCl-modified epitopes in urine is indicative
for neutrophil-/monocyte-mediated respiratory oxidative
burst and tubulointerstitial damage in the kidney [32].
MPO deficiency in mice and humans
While the detection and quantification of MPO-
dependent oxidants may give an insight into a disease
process, studies on MPO knockout (MPO−/−) animals
might elucidate mechanisms of tissue damage mediated
by the MPO-hydrogen peroxide-chloride system; in ad-
dition, adaptive responses to this damage might be recog-
nized. MPO−/− mice with different genetic backgrounds
have been generated [33, 34] and extensively evaluated
in various pathologic processes. Yet, recent findings with
MPO−/− mice in a model of atherosclerosis show that this
mouse model does not necessarily mirror the proathero-
genic action of MPO. Evidence for protein chlorination, a
marker for MPO activity, was neither found in atheroscle-
rotic plaques of wild-type nor MPO−/− mice. Surprisingly,
the lack of MPO in MPO−/− mice was accompanied
by an increased plaque formation [34]. This unexpected
proatherogenic effect might reflect species differences
in pathways involved in the generation of reactive oxy-
gen species and consecutive tissue reaction. Generally,
mice have lower MPO levels in neutrophils than humans
(about 10% to 20% of human levels). Furthermore neu-
trophils of rodents produce more nitric oxide radical than
human neutrophils. Thus, MPO-mediated nitrating re-
actions that exert important effector functions could be
compensated for in the absence of MPO by nitric oxide–
dependent pathways via formation of peroxynitrite. The
fact that MPO also uses nitric oxide as a substrate and
might hence prevent nitric oxide–dependent oxidative
reactions could then represent an alternative hypotheti-
cal explanation for the protective effect of MPO in mice
during development of atherogenesis. Determination of
protein (tyrosine) nitration in mouse models with MPO
deficiency could indicate these compensating oxidant
pathways. This was shown in MPO−/− mice undergoing
brain reperfusion injury in which an increased infarct vol-
ume and elevated nitrotyrosine levels were found 2 hours
after cerebral ischemia as compared to controls [35].
However, analysis of the effect of MPO on the myocar-
dial responses to acute myocardial infarction 72 hours
after ligation of the left anterior descending coronary
artery revealed that MPO−/− mice exhibited significantly
decreased leukocyte infiltration of the infarct area and
delayed earlier death to myocardial rupture [36].
Another possibility to gain insight into functional as-
pects of the MPO-hydrogen peroxide-chloride system
is to study differences between MPO-deficient patients
and controls. Decreased or deficient MPO activity might
be acquired, as shown in case reports in some hemato-
logic diseases (e.g., in acute myelocytic leukemia or in
myelodysplastic syndromes), or more commonly inher-
ited. Primary MPO deficiency is a relatively frequent
event with a prevalence of 2.5 to 7.5 per 10000 people
[37]. It can be attributed to DNA missense muta-
tions/deletions, as well as to impairment of transcrip-
tional activity or attributed to mutations leading to
defective proteolytic processing [38–42]. Generally,
hereditary MPO deficiency has been considered an
autosomal-recessive trait; however, some pedigrees did
not show a simple Mendelian mode of inheritance [38,
43]. Most individuals with inherited MPO deficiency have
a normal phenotype and do not suffer from a markedly
increased risk of infections [44, 45]. Nevertheless, a sig-
nificant higher occurence of severe infections and chronic
inflammatory processes in states with an additional im-
pairment of immune function (e.g., in diabetes mellitus)
was noted. Clinical and laboratory data on acquired MPO
deficiency showed a high incidence of diabetes mellitus
and thrombotic diseases, as well as a strikingly constant
hyperfibrinogenemia in these patients; findings that may
indicate the importance of the relationship between neu-
trophilic granulocytes/monocytes and blood coagulation
[46].
Obviously under physiologic conditions, the lack of
MPO activity is compensated for by other mechanisms
(e.g., increased phagocytic activity and production of su-
peroxide anion radical) [47, 48]. Investigating the course
of immunologic or degenerative renal diseases in MPO-
deficient patients should give valuable insights into the
role of MPO in these diseases. In humans, elevated lev-
els of leukocyte- and blood-MPO are clearly associated
with coronary artery disease [49] and data for a pro-
tective effect of MPO deficiency against cardiovascular
damage were reported [45]. MPO levels are increasing
with age and the A-allele of the G-463-A MPO poly-
morphism was significantly associated with increased lev-
els of apolipoprotein B, total cholesterol, low-density
lipoprotein cholesterol, and triglycerides suggesting a
possible implication of MPO in influencing the risk of
cardiovascular disease [50]; this mutation has a much
higher transcription than the alternative allele [41]. In
humans, MPO may act as a catalyst for (lipo)protein oxi-
dation [6] and the detrimental impact of MPO-dependent
oxidative stress on vascular disease in humans is well
established [2].
MPO in ischemia/reperfusion injury
Ischemia/reperfusion damage is an important pro-
cess in kidney transplantation and can cause delayed
graft function [51]. In the kidney, neutrophils seem
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to be effector cells, although protection against is-
chemia/reperfusion has not been obtained in all pub-
lished studies in animals depleted of neutrophils [52].
Other nonneutrophil-dependent mechanisms evidently
contribute to renal damage and monocytes/macrophages
seem also to be involved in this process. Nevertheless neu-
trophil influx into the kidney is a dominant feature of ex-
perimental ischemia/reperfusion [53]. The fact that these
infiltrating cells are actively engaged in tissue damage is
supported by observations that knockout mice lacking
adhesion molecules (i.e., platelet P-selectin or intercellu-
lar adhesion molecule-1) show reduced neutrophil influx
into the kidney and are partially protected against reper-
fusion injury. Similar results were obtained with antibod-
ies known to block neutrophil adhesion [53]. Migration
of neutrophils into the injured kidney following reperfu-
sion leads to increased renal activity of MPO [54] sug-
gesting a contribution of MPO-dependent chlorinated or
nitrated species to kidney damage. The important role
of the MPO-hydrogen peroxide-chloride system in is-
chemia/reperfusion injury of solid organs is underlined
by the fact that taurine, an important in vivo scavenger
of HOCl, prevented neutrophil-mediated damage in an
ex vivo model investigating ischemia/reperfusion injury
in isolated guinea pig hearts. Furthermore, addition of
taurine ameliorated ischemic preservation of isolated rat
kidneys [55]. On the other hand, systemic application of
taurine did not prevent renal microvascular injury fol-
lowing lower limb reperfusion in rats, although being ef-
fective in ameliorating pulmonary microvascular injury
[56].
Moreover, hydrogen peroxide, the prerequisite for the
generation of MPO-derived oxidants, is present in high
levels following kidney reperfusion. The main source
for the generation of hydrogen peroxide in the kidney
following ischemia/reperfusion is, however, not known.
Superoxide anion radical and its dismutation product,
hydrogen peroxide, may be generated via membrane
NADPH oxidases or produced by the mitochondrial
NAD(P)H dehydrogenase complex in phagocytic
(neutrophils) or nonphagocytic cells (epithelium, en-
dothelium, or fibroblasts) [57, 58]. Another mechanism
of hydrogen peroxide formation by elevated activity of
xanthine oxidase has not been proven to be relevant in
human kidney reperfusion injury. However, in rodent
kidneys, ischemia/reperfusion induces the conversion
of xanthine dehydrogenase, which uses oxidized NAD
as electron acceptor, into xanthine oxidase, which in
contrast uses oxygen as a substrate [59–61]; the time,
though, needed for conversion exeeds the time of
reperfusion-induced generation of reactive oxygen
species. Since adenosine triphosphate (ATP) is con-
sumed during ischemia, the purine catabolites xanthine
and hypoxanthine may accumulate and in the presence
of oxygen, superoxide anion radical, and hydrogen
peroxide could be generated by xanthine oxidase during
reperfusion (for review see [62]).
However, in normal human renal tissue, only low
levels of xanthine oxidase were measured [63, 64]. In
addition minor accumulation of xanthine in human kid-
neys occurred during ischemia suggesting a low activity
of xanthine oxidase and/or dehydrogenase. Nevertheless
xanthine oxidase localized in renal endothelial cells [65]
could at least in part contribute to microvascular ox-
idative injury following reperfusion. Finally, monoamine
oxidases have been discussed as additional sources of
hydrogen peroxide generation in ischemia/reperfusion
[66, 67]. Since substantial levels of monoamine oxidase
are present in human kidney these enzymes could be
likely candidates for hydrogen peroxide supply during
ischemia/reperfusion.
To date, the role of the MPO-hydrogen peroxide-
chloride system in renal ischemia/reperfusion injury
has not been sufficiently documented. The interaction
of MPO with other important pro-oxidant systems in
this process is not well defined (e.g., the interaction
of MPO and inducible nitric oxide synthase in is-
chemia/reperfusion has not been clarified). The lat-
ter enzyme is recognized as an important cofactor in
ischemia/reperfusion injury [68–70]. Nitric oxide, a rel-
atively long-lived free radical, is involved in MPO-
dependent oxidative capacity. As shown for MPO also,
the inducible form of nitric oxide synthase colocalizes
in the primary granules of leukocytes, and following
phagocytic activation, the enzyme is secreted into the
phagolysosome and extracellular compartments, and ni-
tration of bacterial proteins can take place. In contrast to
intraphagosomal chlorination aromatic nitration in neu-
trophils is negligible. The selectivity is different in extra-
cellular media, however, where MPO-catalyzed phenolic
nitration could possibly compete with chlorination [71].
Elevated nitrotyrosine levels present after renal ischemia
and reperfusion may serve as a marker for nitric oxide–
dependent oxidative stress either via formation of per-
oxynitrite or via generation of nitrating species by direct
and/or indirect action of MPO [68, 70]. The lack of the
inducible form of nitric oxide synthase, either following
specific inhibition or gene knockout, resulted in a marked
reduction of MPO activity in mice subjected to renal is-
chemia/reperfusion injury indicating reduced neutrophil
infiltration; furthermore, inhibition of the inducible nitric
oxide synthase significantly decreased protein nitration
and renal injury caused by ischemia/reperfusion in rats
and mice [70].
MPO in degenerative glomerular damage
Lipid-associated glomerulopathy. Monocytes, impor-
tant effector cells in lipid-associated glomerulopathy,
were shown to infiltrate glomeruli during chronic
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hyperlipidemia [72]. These cells are recruited by chemo-
tactic signals (e.g., monocyte chemotactic protein-1 and
macrophage colony-stimulating factor), and expression
of these signals in mesangial cells is induced by different
lipoprotein particles. The expression of CCR2, the recep-
tor for monocyte chemotactic protein-1, is up-regulated
by native and modified lipoproteins.
In the kidney, monocytes represent the major source of
MPO in lipid-associated glomerulopathy a process very
similar to lipid-associated development of atheroscle-
rosis; MPO is associated extracellularly and intracellu-
larly with monocyes/macrophages in different stages of
lesion severity [7]. HOCl-modified (lipo)proteins and
apolipoproteins have been localized in human atheroma
[7, 13, 73] and in material from lesions of homozygous and
heterozygous low-density lipoprotein receptor-deficient
rabbits and rabbits with high response to atherosclerosis
after dietary cholesterol intake [74, 75]. The release of
reactive oxygen species by monocytes evidently can lead
to oxidative modification of lipoproteins, which conse-
quently perpetuate the process of disease. Oxidized-low
density lipoproteins can induce adhesion of monocytes to
glomerular endothelium and HOCl-modified low-density
lipoprotein stimulates production of IL-8 [76]. IL-8,
being also chemotactic for monocytes and T lymphocytes,
stimulates human polymorphonuclear neutrophils for
enhanced production of reactive oxygen metabolites, en-
zyme secretion, and adhesion to endothelial cells [77].
Endothelial cells are unable to generate HOCl via the
MPO-hydrogen peroxide-chloride system themselves,
however, MPO derived from circulating leukocytes may
bind to endothelial cells and endothelial transcytosis of
MPO confers specificity to subendothelial matrix pro-
teins as targets of tyrosine nitration [78]. Recent findings
revealed that low-density lipoprotein, modified by HOCl
in vitro, inhibits nitric oxide synthesis in endothelial cells
via intracellular dislocalization of the endothelial nitric
oxide synthase [79], an important mechanism in the de-
velopment of endothelial dysfunction.
Although different groups and subclasses of scav-
enger receptors do exist, to date, only lectin-like ox-
idized low-density lipoprotein (LOX-1) and scavenger
receptor class B type I (SR-BI) have been identified
as candidate receptors to mediate holoparticle or se-
lective cholesteryl ester uptake from HOCl-modified
lipoproteins on endothelial cells [80]. A recent study in
passive Heymann nephritis, a rat model for human mem-
branous glomerulonephritis, reported that cholesteryl
ester increments in glomeruli and proximal tubular seg-
ments were associated with decreased SR-BI expression
[81]. These observations support the notion that this re-
ceptor is primarily contributing to cholesterol/cholesteryl
ester hemeostasis in the kidney. It has not been stud-
ied whether HOCl-modified (lipo)proteins may severely
impair SR-BI–mediated bidirectional cholesterol flux in
the kidney as discussed for peripheral tissues and the
liver, respectively [73]. Expression of LOX-1 is increased
in ischemia/reperfusion of rat kidney [82] and diabetes-
associated conditions in vitro and in vivo [83]. As LOX-1
also serves as a receptor for AGEs, binding of MPO-
generated adducts via LOX-1 may similarly introduce
oxidative stress, reduce nitric oxide, promote generation
of superoxide anion radical, and activate nuclear factor-
kappaB (NF-jB), resulting in changes in gene expression
(chemokines and adhesive molecules) and cellular phe-
notpye (activation or apoptosis) in the kidney. LOX-1
expression is also up-regulated in experimental hyper-
tensive glomerulosclerosis and in the remnant kidney,
an established rat model for chronic renal failure. Stain-
ing for LOX-1 was primarily observed in the interstitial
cells [84]. Reduction of blood pressure by specific an-
giotensin II type I receptor antagonists was associated
with suppressed renal LOX-1 expression [84]. Taurine
protected against renal damage induced by salt load-
ing in Dalt salt-sensitive rats; this was accompanied by
suppression of LOX-1 [85], although the exact patho-
physiologic meaning of these associations has not been
elucidated.
Diabetic nephropathy. Blood neutrophils in diabetic
patients show reduced MPO activity [86]; however,
the activity is restored after stimulation of neutrophils
with formyl-methionyl-leucyl-phenylalanine [87]. Since
MPO-derived oxidants are capable of forming AGEs [21,
88], a link between the MPO-hydrogen peroxide-chloride
system, the generation of AGEs and subsequent interac-
tion with RAGE may be assumed. RAGE is expressed
at low abundance in renal endothelial cells, podocytes
or parietal epithelium; however, its expression is up-
regulated in these cells under various pathologic con-
ditions, including diabetic nephropathy [89]. Binding of
AGEs to RAGE leads to prolonged activation of NF-jB
in mononuclear and endothelial cells [90]. Up-regulation
of proinflammatory genes ensues on polymorphonu-
clear neutrophils, monocytes/macrophages, and endothe-
lial cells such as expression of adhesion molecules (e.g.,
intercellular adhesion molecule type 1, vascular cell ad-
hesion molecule 1, or E-selectin) [91], which enhance the
adhesion and transmigration of mononuclear cells.
Interestingly, pronounced MPO activity has been de-
tected in epiretinal membranes of patients suffering from
proliferative diabetic retinopathy in contrast to mem-
branes of patients with proliferative vitreoretinopathy
and macular pucker, pointing toward a significant role
of MPO in this diabetic vascular complication [92]. How-
ever, increased MPO activity has not been reported in di-
abetic nephropathy. It is still speculative to regard MPO
as a relevant pathogenetic factor for renal complications
in diabetes. Epidemiologic studies in diabetic patients
with MPO deficiency would represent a valuable cohort
to clarify the role of MPO.
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MPO in immunologic glomerular disease
Membranous glomerulonephritis. The pathogenesis of
human membranous glomerulonephritis has not been
fully elucidated although major aspects were deduced
from passive Heymann nephritis where reactive oxy-
gen species seem to play a prominent role in the
induction of pathophysiologic sequelae such as protein-
uria [93, 94]. In passive Heymann nephritis, glomerular
epithelial cells may generate hydrogen peroxide by ex-
pressing NAD(P)H-dependent oxidoreductase in anal-
ogy to neutrophilic granulocytes during the respiratory
burst reaction. Evidence for a role of the MPO-hydrogen
peroxide-chloride system in the synthesis of reactive oxy-
gen species in damaged glomerular basement membranes
from patients with membranous glomerulonephritis [15]
was based on immunohistochemistry of HOCl-modified
proteins/epitopes colocalizing with immune deposits in
affected glomeruli (Fig. 2). In parallel, staining inten-
sity for HOCl-modified epitopes highly correlated with
staining intensity for MPO in glomerular basement mem-
branes and the presence of mononuclear cell infiltrates,
respectively. This indicates a substantial role of these cells
during development of human membranous glomeru-
lonephritis [15]. This must be seen in the context that
monocytes, not generally accumulating in membranous
glomerulopathy [95, 96], can apparently contribute to
the pathogenesis in later stages of the disease with de-
teriorating kidney function. There is only scant knowl-
egde about MPO in other forms of immune complex
glomerulonephritis (e.g., IgA nephritis). HOCl-modified
(lipo)proteins were identified in urine of hyperlipidemic
rats with mesangioproliferative glomerulonephritis but
not in normolipidemic animals with glomerulonephritis
[32].
Antineutrophil cytoplasmic antibody (ANCA)-positive
small vessel disease-necrotizing glomerulonephritis. In
ANCA-positive necrotizing glomerulonephritis pro-
nounced glomerular infiltration with neutrophils and
monocytes is found [24, 97]. MPO- and proteinase
3-ANCAs, which bind to MPO or proteinase 3, respec-
tively, recognize specific epitopes on the surface of poly-
morphonuclear neutrophils. It is generally assumed that
they are a common feature of vasculitis of small ves-
sels. ANCAs are suggested to contribute to the patho-
genesis of this disease [98–100]. At least in the case
of MPO-ANCAs, recent findings strongly indicated a
causative role: Splenocytes from MPO−/− mice immu-
nized against MPO were injected into Rag−/− mice (lack-
ing functional lymphocytes) and induced a crescentic
glomerulonephritis with a paucitiy of immune deposits
and a systemic necrotizing vasculitis; an analogous ef-
fect occured following application of purified anti-MPO
IgG [101]. Whether ANCAs directed against MPO or
against proteinase 3 induce different effects has not been
reported.
Fig. 2. Immunohistologic staining for (A) myeloperoxidase (MPO)
and MPO-positive cells (arrowheads show mononuclear cells within
capillaries; arrows show staining at the glomerular basement mem-
brane) and for (B) HOCl-modified proteins/epitopes in glomeruli of
stage II membranous glomerulonephritis (arrows show intramembra-
nous granular label). Adapted and modified with permission from
reference [15].
Neutrophils are activated by ANCAs; this activation
leads to enhanced binding of polymorphonuclear neu-
trophils to the endothelial layer and to production of su-
peroxide anion radical and hydrogen peroxide during the
oxidative burst [98, 102, 103]. Hydrogen peroxide may
serve for the generation of HOCl and for nitric oxide
synthase-independent, nonenzymatic formation of nitric



































Fig. 3. Myeloperoxidase (MPO)- or proteinase-3 (PR3)-directed antineutrophil cytoplasmic antibodies (ANCAs) bind to neutrophils and lead to
stimulation. Furthermore, apoptotic bodies of neutrophils are opsonized by ANCAs and are phagocytosed subsequently by macrophages. Activation
of macrophages results in secretion of chemotactic factors that enhance neutrophil influx. Tumor necrosis factor-a (TNF-a) released by macrophages
is propagating neutrophil apoptosis while cytokines [interleukin-1 (IL-1) and interleukin-8 (IL-8)] mediate chemotaxis. MPO released by activated
neutrophils during the oxidative burst generates HOCl while nitric oxide radical (NO) is generated by nitric oxide synthases [inducible nitric
oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS)]. Reactive nitrogen intermediates (NOx), also generated by MPO may lead to
endothelial damage. Inactivation of MPO by ceruloplasmin is prevented by MPO-ANCA.
oxide [104]. Thus, ANCA-stimulated neutrophils are pro-
ducing a variety of oxidants leading to endothelial dam-
age [105]. Moreover MPO-ANCA prevents inactivation
of MPO by ceruloplasmin, a plasmatic binding inhibitor
of MPO [106]; this contributes to a higher MPO activity
and increased generation of HOCl at sites of inflamma-
tion. ANCA-stimulated neutrophils release epitopes into
supernatant that are recognized by MPO-ANCAs and
that bind to the cell surface of unstimulated neutrophils;
the binding of these epitopes on unstimulated neutrophils
renders them responsive to activation by MPO-ANCAs
[103]. Whether the surface structure on neutrophils rec-
ognized by MPO-ANCAs corresponds to intact and en-
zymatically active MPO is, however, unproven.
Following activation by ANCAs, polymorphonuclear
leukocytes can undergo apoptosis. Apoptotic bodies are
opsonized by ANCAs and phagocytosed efficiently by
macrophages [102] (Fig. 3). Apoptotic neutrophils op-
sonized with proteinase 3-ANCAs stimulated phagocy-
totic activity and production of TNF-a in macrophages
[107]. Vice versa TNF-a induced apoptosis and ex-
pression of epitopes, which are recognized by both
MPO- and proteinase 3-ANCAs in neutrophils [108]. Fur-
thermore, IL-1 or IL-8, consecutively secreted from ac-
tivated macrophages, help to sustain the inflammatory
process [102]. These cytokines are chemotactic for neu-
trophils and may lead to faster neutrophil-influx into the
inflamed site, thus providing a self-amplifying inflamma-
tory process.
Epidemiologic studies in MPO-deficient patients. Re-
cently, substantial progress has been made in the char-
acterization of connections between the MPO-hydrogen
peroxide-chloride system and other oxidative pathways
so that a very complex tableau of interacting reactions is
emerging. To further elucidate the biologic relevance and
consequence of different pathways well-defined in vivo
models are required. However, as already mentioned,
observations in MPO−/− mice have shown interspecies
differences for oxidative pathways, suggesting that ob-
servations from animal models can only be transfered
very carefully to humans. Thus, a most promising alterna-
tive may be provided by epidemiologic studies in MPO-
deficient patients.
Modulation of the MPO-hydrogen peroxide-chloride
system for treatment of inflammatory/degenerative
kidney diseases
Studies with MPO−/− mice indicated possible MPO-
mediated beneficial effects in inflammatory/degenerative
1964 Malle et al: Myeloperoxidase in kidney disease
diseases [34, 35]. Thus, it is intriguing to speculate
that protective effects could also occur under certain
circumstances in kidney diseases. Several mechanisms
by which MPO could exert antiinflammatory effects
can be conceptualized. The MPO-hydrogen peroxide–
chloride system can act as an antagonist to the nitric ox-
ide/peroxynitrite pathway. Furthermore, MPO-derived
chloramines, specifically taurine chloramines, have anti-
inflammatory effects. Taurine chloramine can inhibit cy-
tokine production by leukocytes and impair and/or block
expression of monocyte chemoattractant protein-1, radi-
cal generation, and nitric oxide synthesis in macrophages
[109, 110]. Obviously, many of these effects are caused by
stabilizing oxidation of I-jB and inhibition of NF-jB ac-
tivation [111]. In addition, the MPO-hydrogen peroxide-
chloride system can downregulate NADPH oxidase
activity. Conversely, nitric oxide, either generated by en-
dothelial nitric oxide synthase at low concentrations or
generated by inducible nitric oxide synthase at high con-
centrations, can inhibit MPO activity albeit by different
concentration-dependent mechanisms.
Possible therapeutic options to influence the MPO-
hydrogen peroxide-chloride system. An influence upon
the MPO-hydrogen peroxide-chloride system might be
exerted by the inhibition of MPO with 3-amino-1,2,4-
triazole, 4-aminobenzoic acid hydrazide, dapsone, or iso-
niazide. However, it is not proven that these inhibitors
can be administered in such doses that one would achieve
sufficient tissue concentrations in vivo to produce re-
liable MPO blockade without intolerable side-effects.
Nevertheless, the major physiologic and most favoured
substrate for MPO is thiocyanate [112] and hypothiocyan-
ite, the corresponding oxidation product, is innocuous to
mammalian cells. Thus it is conceivable that thiocyanate
may limit bacterial killing and neutrophil-mediated tis-
sue damage by diverting hydrogen peroxide away from
the production of HOCl.
Another possibility is the application of antioxi-
dants (e.g., ambroxol, dithiocarbamate and vitamin C)
[113] that protect against or even may reverse HOCl-
and chloramine-dependent modification of proteins by
pathways probably involving intracellular levels of re-
duced glutathione and ATP. Even phenolic compounds
(e.g., chlorogenic acid) might be considered as HOCl
scavengers.
The prophylactic administration of pharmacologic
doses of taurine protects various tissues from damage in
several different paradigms where inflammation is likely
to be pathologically involved. Taurine, in addition to its
potent effects to lower the incidence of cardiovascular
disease and atherosclerosis, may act as a potent HOCl
trap in the kidney, an organ responsible for the regula-
tion of the total taurine pool. The protective effect of this
nonprotein sulfur containing amino acid in rat models of
human kidney disease [114] and attenuation of age-
related renal interstitial fibrosis has been reported [115,
116]. In parallel, taurine ameliorated chronic renal lesions
in streptozocin-induced diabetes mellitus in rats [117] by
decreasing total proteinuria and albuminuria, preventing
glomerular hypertrophy, diminishing glomerulosclerosis
and tubulointerstitial fibrosis, and decreasing the forma-
tion of AGEs.
More clinical experience is available for a contrasting
approach. HOCl donor tetrachlorodecaoxide is currently
used for topical application in wound-healing disorders
and for systemic application as a modulator of mono-
cyte functions in patients with AIDS [118]. Furthermore,
animal studies were performed in which tetrachlorode-
caoxide was used as a posttransplantation immunosup-
pressant [119]. Tetrachlorodecaoxide is activated by a
reaction with hemoproteins by a two-electron transfer
leading to generation of HOCl [120]. Its immunomodu-
latory properties might be in part due to production of
chloramines (e.g., taurine chloramines). It thus is appar-
ent that inhibition as well as stimulation of the MPO-
hydrogen peroxide-chloride system may have beneficial
effects on the course of disease process; this dual ambiva-
lent action may well to be dependent on the stage of the
respective renal disease.
OUTLOOK
It is now evident that the MPO-hydrogen peroxide-
chloride system plays a relevant role not only in oxidant-
mediated antimicrobial defense by granulocytes but also
in the progression of degenerative and immunologic dis-
eases of the kidney. The intricate interaction of MPO and
its products with other oxidant systems, specifically the
nitric oxide pathway, shows the complexity of the redox
system. These interactions of oxidant components and
the varying biological actions of HOCl concentrations
generated in vivo in different disease settings may ex-
plain either beneficial or detrimental effects of the MPO-
hydrogen peroxide-chloride system. MPO−/− mice tend
to incur more acute damage (e.g., brain infarct) and to
suffer more chronic vascular damage (e.g., atherosclero-
sis) than wild-type animals. Drugs that generate HOCl
could be immunomodulatory and even enhance wound
healing. Yet it seems undisputed that MPO contributes
to atherosclerosis and exerts a major influence in the
pathophysiology of microscopic polyangitis and necro-
tizing glomerulonephritis. The precise pathophysiologic
role though of the MPO-hydrogen peroxide-chloride sys-
tem in the majority of human kidney diseases still has to
be investigated in detail. Urinary measurement of MPO-
mediated protein, lipid, and carbohydrate modifications
(including generation of AGEs), immunohistologic and
biochemical evidence for reactive MPO-dependent oxy-
gen and nitrogen species and specific inhibition of MPO
activity may help to elucidate the participation of MPO
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in human glomerular and interstitial disease. Epidemio-
logic studies of patients with genetic defects in MPO and
the study of MPO polymorphisms will probably give fur-
ther insight into a postulated role of this unique enzyme
and its oxidation products in renal disease.
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